articles
- Virus reactivation in a non-cirrhotic HBV patient requiring liver transplantation after cessation of nucleoside analogue therapy. 26:3-8. 2021
- Vitamin D time profile based on the contribution of non-genetic and genetic factors in HIV-infected individuals of European ancestry. 20:261-269. 2015
- Efavirenz intoxication due to a new CYP2B6 constellation. 18:739-743. 2013
- Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women. 18:171-182. 2013
- Pathogenic effects of Rift Valley fever virus NSs gene are alleviated in cultured cells by expressed antiviral short hairpin RNAs. 17:643-656. 2012
- Successful efavirenz dose reduction guided by therapeutic drug monitoring. 16:189-197. 2011
- Adverse events to antiretrovirals in the Swiss HIV Cohort Study: Effect on mortality and treatment modification. 12:1157-1164. 2007
- Does tenofovir influence efavirenz pharmacokinetics?. 12:115-118. 2007
- Identifying safety concerns from genetic data: lessons from the development of CCR5 inhibitors. 12:147-148. 2007
- Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies. 12:639-650. 2007
- Naive HIV/HCV-coinfected patients have higher intrahepatic pro-inflammatory cytokines than coinfected patients treated with antiretroviral therapy. 11:385-389. 2006